T. A. Ponomarenko

T. A. Ponomarenko

Auto-generated profile, based on publicly available information

T. A. Ponomarenko

Kuban State Medical University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2026 in Kuban Scientific Medical Bulletin
Verified
Journal Article
Open access
PDF file
MMM. N. Mitropanova
M. N. Mitropanova
TPT. A. Ponomarenko
T. A. Ponomarenko
GCG. A. Chudilova
G. A. Chudilova
SKS. V. Kovaleva
S. V. Kovaleva
IKI. I. Kartashevskiy
I. I. Kartashevskiy
SMS. D. Morenko
S. D. Morenko
Background . Treatment of children with suppurative maxillofacial space infections remains an ongoing problem, which is exacerbated by the growing microbial resistance and immune response dysfunction that can prolong the recovery process. Objective . To analyze the clinical and immunological effects of using an immunomodulator based on a synthetic hexapeptide (Imunofan) in a combination therapy of suppurative maxillofacial space infections in children. Methods . A prospective nonrandomized comparative pilot trial was conducted. The study included 47 children aged 8–17 years with suppurative maxillofacial space infections, who were comparable in terms of the baseline data. The patients received either the standard treatment (surgical debridement + antibiotics; n = 27, Subgroup 1) or the standard treatment supplemented with Imunofan (45 µg/day intramuscularly for five days; n = 20, Subgroup 2). The comparison group comprised 13 relatively healthy children. The study assessed the subpopulations of lymphocytes (via flow cytometry), the levels of immunoglobulins, and the phagocytic activity of neutrophilic granulocytes. The obtained data were processed using Microsoft Excel 2019 (Microsoft, USA) and an online calculator (https://medstatistic.ru). In order to control the risk of Type I errors in the multiple comparisons of immunological parameters, the Holm-Bonferroni correction was used. After correction, the significance level was set at p < 0.05. Results . Prior to treatment, the children with suppurative maxillofacial space infections were found to have combined immune disorders: decreased relative count of T lymphocytes, helper T cells (CD3+CD4+ ), and cytotoxic lymphocytes (CD3+CD8+ ), as well as incomplete phagocytosis. The standard treatment (Subgroup 1) normalized only the leukocyte level (p < 0.05 after correction), while cellular immunity and phagocytic function remained impaired. In Subgroup 2, a clear tendency was observed toward the normalization of median T-cell parameters (T lymphocytes: 76.1% in Subgroup 2 vs. 75.73% in the comparison group; helper T cells: 46.75% vs. 46.05%) and significantly improved completeness of phagocytosis; however, after correction for multiple comparisons, no statistically significant differences were found in most immunological parameters between Subgroup 2 and the comparison group. The key clinical outcome was a statistically significant reduction in the hospital length of stay in Subgroup 2 as compared to Subgroup 1 (8.70 ± 2.49 vs. 12.89 ± 1.50 days, p = 0.02). Conclusion . The study results indicate the potential efficacy of Imunofan immunomodulator in the combination therapy of suppurative maxillofacial space infections in children, which manifests itself in the positive changes in the immunological parameters and a significant reduction in the hospital length of stay. The obtained data justify further randomized controlled effectiveness trials.

22 September 2023 in Russian Journal of Immunology
Verified
Journal Article
Open access
PDF file
MMMarina N. Mitropanova
Marina N. Mitropanova
TPT. A. Ponomarenko
T. A. Ponomarenko
GCG. A. Chudilova
G. A. Chudilova
YTYu. V. Teterin
Yu. V. Teterin
VCV. N. Chapurina
V. N. Chapurina
The issues of treatment of purulent inflammatory diseases of the maxillofacial region (PMMA) are quite urgent, due to increasing number of such patients. Their clinical course is getting worse, and the efficiency of antibiotic therapy is decreasing. Clinical outcomes of purulent maxillofacial pathology in children are complicated by potential severe local deformities at the growth areas of the jaw bones which are difficult to eliminate. The number of cases of prolonged and chronic inflammatory processes, development of local and general complications is increased. The reason for these complications may be an impaired susceptibility to infectious agents, which is determined by the state of the immune system. Therefore, our aim was to reveal some features of immune functions in children with purulent-inflammatory diseases of maxillofacial area. The study included a group of pediatric patients 8-17 years old with maxillofacial inflammatory diseases of the maxilla (the study group), and 13 conditionally healthy children (the comparison group). The contents of T cells (CD3+CD19-, CD3+CD4+, CD3+CD8+, CD3+CD4+/CD3+CD8+), and В cells (CD3-CD19+), NK (CD3-CD16+CD56+) was determined using Cytomics FC-500 (Beckman Coulter, USA);concentrations of serum IgA, IgM, IgG were determined by ELISA technique (Vector-Best, Russia). Phagocytic activity of neutrophilic granulocytes (NG) was evaluated as percentage of actively phagocytic NGs, capturing processes were assessed by appropriate phagocytic indices, and the digestive activity was evaluated against S. aureus (strain 209). Combined defects of immune response in children with maxillofacial hypertension were established: decrease of T lymphocytes contents along with decrease of T helpers and CTL ratio along with unchanged content of NK cells and B lymphocytes. Increase of IgA and IgG levels was also found. Defects of phagocytosis were revealed, primarily connected with the processes of completed phagocytosis and increased content of actively phagocytizing NG. Treatment of children suffering with purulent inflammatory diseases of maxillofacial region is still an urgent problem in dentistry. The revealed dysfunction of immune response to pathogens in the purulent maxillofacial disorders may explain a prolonged clinical course of inflammatory processes, thus determining a need for usage of immunotropic therapy in complex treatment schedules including operative aid as well as conventional drug and physiotherapeutic treatment aiming for increase of rehabilitation efficiency and prevention of postoperative complications in these patients.

18 July 2023 in Clinical Dentistry (Russia)
Verified
Journal Article
Open access
PDF file
МММ.н. Митропанова
М.н. Митропанова
ТПТ.а. Пономаренко
Т.а. Пономаренко
ЕЛЕ.о. Любомирская
Е.о. Любомирская
ЕФЕ.н. Фролкина
Е.н. Фролкина
САС.ш. Антониадис
С.ш. Антониадис
ВЗВ.я. Зобенко
В.я. Зобенко
Цель исследования — оценить распространенность воспалительных заболеваний челюстно-лицевой области (ЧЛО) у детей. Проведен анализ заболеваемости у детей, поступивших в отделение челюстно-лицевой хирургии Краснодарской краевой клинической больницы с 2017 по 2021 г. Изучали истории болезни 8313 пациентов, а также ежегодные статистические отчеты отделения. Распространенность воспалительных заболеваний ЧЛО в среднем составила 42,9%. Наибольшая доля воспалительных заболеваний приходится на 2020 г. — 46,1%. Самый низкий результат обнаружен в 2017 г. — 37,8%. В структуре воспалительных заболеваний преобладают одонтогенные процессы, которые в среднем составляют 73,2% и варьируют от 64,1% в 2017 г. до 78,1% в 2020 г. Доля опухолей и опухолеподобных состояний ЧЛО составляла от 27,4% в 2020 г. до 39,0% в 2017 г. (в среднем — 33,9%). Госпитализации по поводу врожденных пороков развития ЧЛО составляли от 10,8% в 2019 г. до 14,7% в 2017 г. (в среднем — 12,6%). Травматические поражения ЧЛО составили от 8,5% в 2017 г. до 13,4% в 2020 г. (в среднем — 10,4%). Выявлены высокие показатели и неуклонный рост количества больных детей с воспалительными заболеваниями ЧЛО, преимущественно одонтогенной этиологии, некоторое снижение доли заболеваний с опухолями и опухолевидными состояниями. The aim of this study was to estimate the prevalence of inflammatory diseases of the maxillofacial region in children. . We analyzed the diseases of children admitted to the Maxillofacial surgery Division of the Krasnodar Regional Clinical Hospital in 2017—2021. Case histories of 8313 patients were studied, as well as the annual statistical reports of the hospital. . The prevalence of inflammatory diseases of the maxillofacial region averaged 42.9%. The highest proportion of inflammatory diseases was in 2020 — 46.1%. The lowest result was found in 2017 — 37.8%. The structure of inflammatory diseases is dominated by odontogenic processes, which averaged 73.2% and ranged from 64.1% in 2017 to 78.1% in 2020. The proportion of tumors and tumor-like conditions ranged from 27.4% in 2020 to 39.0% in 2017 (33.9% on average). Hospitalizations for congenital malformations of the choroid ranged from 10.8% in 2019 to 14.7% in 2017 (12.6% on average). Traumatic lesions of the maxilla ranged from 8.5% in 2017 to 13.4% in 2020 (10.4% on average). . High rates and a steady increase in the number of children with inflammatory diseases of the maxillae, mainly of odontogenic etiology, and a slight decrease in the proportion of diseases with tumors and tumor-like conditions have been revealed.

25 September 2026 in Clinical Dentistry (Russia)
Verified
Journal Article
Closed access
MMM.N. Mitropanova
M.N. Mitropanova
TPT.A. Ponomarenko
T.A. Ponomarenko
GCG.A. Chudilova
G.A. Chudilova
SKS.V. Kovaleva
S.V. Kovaleva
AAA.A. Avedisyan
A.A. Avedisyan
In pediatric dentistry, the treatment of purulent-inflammatory pathologies of the maxillofacial region in children remains a pressing issue. The immune system (IS) disorders detected in these diseases often lead to the chronicization of the inflammatory process, which necessitates the use of immunomodulatory drugs as part of a comprehensive treatment approach. The aim of the study is to evaluate the effectiveness of comprehensive treatment, including the use of the drug Imunofan®, on the clinical course and immunological parameters in children with purulent-inflammatory diseases of the maxillofacial region. Materials and methods. The study included children aged 8—17 years with purulent-inflammatory diseases of the maxillofacial region (PID MFR). The study group (SG) consisted of 47 patients before treatment. Patients receiving standard therapy were included in SG1 after treatment; their number amounted to 27 children. SG2 after treatment included 20 children who received comprehensive treatment, in which standard therapy was supplemented with the administration of the drug Imunofan®. The comparison group (CG) included 13 conditionally healthy children. The content of T-lymphocytes (CD3+CD19−, CD3+CD4+, CD3+CD8+, CD3+CD4+/CD3+CD8+) and B-lymphocytes (CD3−CD19+), NK-cells (CD3−CD16+CD56+), as well as the concentration of serum IgA, IgM, and IgG, were determined. The phagocytic activity of neutrophilic granulocytes (NG) was assessed by the number of actively phagocytic NG (%FAN), the uptake processes by the indicators (FC, FI), and the digesting activity by %P and IP in relation to S. aureus (strain No. 209). Results. Combined defects in the functioning of the immune system have been identified in children with GVI of the maxillofacial region (GI before treatment): a decrease in the content of T-lymphocytes with a parallel reduction in the proportion of T-helper cells and cytotoxic lymphocytes (CTLs), against the background of unchanged content of NK cells and B-lymphocytes. At the same time, an increase in the levels of IgA and IgG has been established. Defects in phagocytosis have been identified, associated with a decrease in the digestive activity of NG cells. In GI2, after treatment, there was a restoration of the impaired parameters of T-cell and humoral immunity, as well as the effector functions of NG, which was accompanied by more significant clinical effects in children who received comprehensive treatment including GP immunotherapy. Conclusion. The positive clinical and immunological effect of using the pharmaceutical product Imunofan® in the comprehensive treatment of children with PID MFR has been demonstrated. Immunocorrection of immune system dysfunction in this pathology demonstrates significant advantages compared to the use of standard therapy alone.

21 October 2024 in Pediatric dentistry and dental prophylaxis
Verified
Journal Article
Open access
PDF file
TPT. A. Ponomarenko
T. A. Ponomarenko
MMM. N. Mitropanova
M. N. Mitropanova
SAS. S. Antoniadis
S. S. Antoniadis
ELE. O. Lyubomirskaya
E. O. Lyubomirskaya
AOA. V. Olenskaya
A. V. Olenskaya
EFE. N. Frolkina
E. N. Frolkina
Relevance. Acute purulent-inflammatory diseases of the maxillofacial region (APID-MFR) are the leading cause of pediatric referrals to the maxillofacial surgery department. The prevalence of APID-MFR requiring hospitalization among children in Krasnodar and Krasnodar Krai averaged 42.9% from 2017 to 2021.Objective. To investigate the nature and structure of odontogenic and non-odontogenic inflammatory processes in patients treated at the maxillofacial surgery department of the State Healthcare Institution "Children’s Regional Clinical Hospital" (CRCH), Krasnodar.Materials and methods. Medical records of patients with inflammatory diseases of the maxillofacial region, treated in the maxillofacial surgery department at CRCH, Krasnodar, from 2017 to 2021, were analyzed. The study focused on examining the structure and characteristics of the pathology in patients receiving inpatient care.Results. The most common pathology identified in children was periostitis (30.9%), which significantly differed (p = 0.007) from the second most prevalent condition, exacerbation of chronic periodontitis (26.1%). The third place was shared by lymphadenitis (13.6%) and inflammatory skin and subcutaneous tissue diseases, including boils and carbuncles (13.5%), both of which significantly differed from the top two conditions (p < 0.001) but not from each other (p > 0.05). In fourth, fifth, and sixth places were other inflammatory skin and subcutaneous tissue diseases: abscess (10.1%), phlegmon (4.8%), and adenophlegmon (1.0%), which also significantly differed from one another.Conclusion. The high prevalence of odontogenic APID-MFR in children highlights the insufficient prevention of caries-related complications and emphasizes the need for enhanced pediatric dental care. Early diagnosis and prevention of APID-MFR complications are crucial to improving outcomes in affected children.